Table 2 Summary of patient and treatment characteristics at the start of treatment courses by treatment.
Variable | TOFa (n = 345 TCs) | bDMARDsa (n = 1893 TCs) |
|---|---|---|
Age (years), median (IQRb) | 59 (50–69) | 57 (48–66) |
≥ 50, n (%) | 263 (76.2) | 1333 (70.4) |
≥ 65, n (%) | 126 (36.5) | 522 (27.6) |
Female sex, n (%) | 270 (78.3) | 1413 (74.6) |
Seropositivityc, n (%) | 226 (67.0d) | 1406 (75.7d) |
Disease duratione (years), median (IQRb) | 8 (4–17) | 6 (2–14) |
Concomitant csDMARDsf, | 175 (50.7) | 1313 (69.4) |
Concomitant oral GCSg | 133 (38.5) | 622 (32.9) |
Known history of SIh, n (%) | 16 (4.6) | 47 (2.5) |
Delayed entry into risk set, n (%) | ||
Start prior to study entry | 141 (40.9) | 1229 (64.9) |
Initially overlapping exposure | 63 (18.3) | 169 (8.9) |
Previous exposure to treatment, n (%) | 25 (7.2) | 265 (14.0) |
Initial dosing regimen, n (%) | ||
5 mg BIDi | 273 (79.1) | |
5 mg ODi | 18 (5.2) | |
10 mg BIDi | 11 (3.2) | |
10 mg ODi | 38 (11.0) | |
Other | 5 (1.4) | |
Identity of bDMARD, n (%) | ||
Abatacept | 314 (16.6) | |
Adalimumab | 227 (12.0) | |
Anakinra | 1 (0.0) | |
Certolizumab | 105 (5.5) | |
Etanercept | 227 (12.0) | |
Golimumab | 174 (9.2) | |
Infliximab | 139 (7.3) | |
Rituximab | 364 (19.2) | |
Tocilizumab | 342 (18.1) |
